Jiangsu Chia Tai Tianqing Pharmaceutical Group and collaborators describe GTPase KRAS inhibitors March 29, 2021
HMPL-306 enters international phase I studies in solid tumors and hematological malignancies March 29, 2021
Intensity Therapeutics to conduct phase II study of INT230-6 in early-stage breast cancer March 29, 2021
RSS